IPP Bureau
Lupin launches Prucalopride tablets in US
By IPP Bureau - June 27, 2025
Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA
Philogen withdraws marketing authorization application for Nidlegy in EU
By IPP Bureau - June 26, 2025
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
Dr. Lal PathLabs strengthens its genomics capabilities with Illumina's NovaSeq X Series
By IPP Bureau - June 26, 2025
The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability
Ashland expands viatel bioresorbable polymers offering for medical devices
By IPP Bureau - June 26, 2025
Viatel bioresorbable polymers are increasingly used in dental and orthopedic implants
Covestro launches localized production of medical-grade TPU in Asia Pacific
By IPP Bureau - June 25, 2025
Changhua site meets international regulatory standards for global medical applications
Glenmark Pharmaceuticals launches TEVIMBRA in India
By IPP Bureau - June 25, 2025
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
Briefs: J B Chemicals and Pharmaceuticals, Concord Biotech and Gland Pharma
By IPP Bureau - June 25, 2025
J B Chemicals and Pharmaceuticals receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA
Bachem expands multi-site production capacities to meet rising demand
By IPP Bureau - June 25, 2025
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
Lupin receives USFDA approval for Prucalopride Tablets
By IPP Bureau - June 25, 2025
Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation in adults
Archish Fertility & IVF partners with Amaha Health for patient support and mental wellbeing
By IPP Bureau - June 24, 2025
This collaboration ensures that patients receive comprehensive care, including emotional and psychological support throughout their fertility journey
Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
By IPP Bureau - June 24, 2025
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
Biocon Biologics collaborates with National Cancer Society Malaysia
By IPP Bureau - June 24, 2025
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
Merck announces Phase 3 hyperion study of Winrevair met primary endpoint in recently diagnosed adults with PAH
By IPP Bureau - June 24, 2025
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1
By IPP Bureau - June 23, 2025
Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plants by volume
